Xbrane Biopharma (XBRANE) investor relations material

Portfolio and market opportunity

• Three biosimilar programs: Lucamzi for Lucentis, Xdivane for Opdivo and earlier-stage Xdarzane for Darzalex.

• Lucamzi has FDA approval; Xdivane targets a market where Opdivo and Keytruda together generate $40bn in sales, while Darzalex is a $14bn originator product.

Lucamzi commercialization

• Ximluci has been commercialized by STADA in 24 European countries for three years, under a 50/50 profit-sharing arrangement.

• European profit sharing has generated close to SEK 150m cumulatively, or about SEK 50m annually; SEK 150m of inventory is expected to convert to cash during the remainder of 2026 and in 2027.

• U.S. launch preparations with Valorum are underway, including QCO application and commercial production, targeting mid-2027; the speaker cited a EUR 9bn ophthalmic VEGF-inhibitor market.

Xdivane development

• Pivotal melanoma trial fully recruited 340 patients; Q2 2027 readouts are expected, followed shortly by FDA submission, with U.S. launch targeted for the Dec. 2028 patent expiry.

• The speaker said Xdivane is on track to launch on day one after patent expiry and is near the front of the biosimilar race, behind Amgen; Intas and Accord are commercialization partners.

• Drug substance and drug product will be made at separate European sites operated by a top-10 global contract manufacturer; the speaker said this experience reduces GMP-related approval risk.

• An external valuation firm estimated potential peak profit sharing above EUR 100m; realization remains an opportunity rather than a stated outcome.